Upstream Bio (UPB) Income towards Parent Company (2023 - 2026)
Upstream Bio (UPB) recorded quarterly Income towards Parent Company of -$40.6 million in Q1 2026, up 4.59% quarter-over-quarter from -$42.5 million in Q4 2025, and down 48.74% on a YoY basis from -$79.1 million in Q1 2025.
Upstream Bio (UPB) Income towards Parent Company (2023 - 2026) Analysis & Trends
Upstream Bio's Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$40.6 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 48.74% year-over-year to -$40.6 million; the TTM figure through Mar 2026 stood at -$156.7 million (down 97.97% YoY), while the FY2025 annual figure was -$143.4 million, down 118.5% from the prior year.
- Income towards Parent Company was -$40.6 million for Q1 2026 at Upstream Bio, up from -$42.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$7.9 million in Q3 2023 to a low of -$42.5 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$24.6 million across 4 years, with a median of -$21.2 million in 2024.
- The sharpest annual moves came in 2025 and 2026: Income towards Parent Company sank 172.22% in 2025, then sank 48.74% in 2026.
- A 4-year view of Income towards Parent Company shows it stood at -$12.8 million in 2023, then tumbled by 65.81% to -$21.2 million in 2024, then tumbled by 100.14% to -$42.5 million in 2025, then grew by 4.59% to -$40.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$40.6 million (Q1 2026), -$42.5 million (Q4 2025), and -$33.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.56 Mn |
| Dec 31, 2025 | -42.51 Mn |
| Sep 30, 2025 | -33.73 Mn |
| Jun 30, 2025 | -39.92 Mn |
| Mar 31, 2025 | -27.27 Mn |
| Dec 31, 2024 | -21.24 Mn |
| Sep 30, 2024 | -15.99 Mn |
| Jun 30, 2024 | -14.66 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -12.81 Mn |
| Sep 30, 2023 | -7.86 Mn |